|
No images? Click here
Arbovirus Gazette - October 2026 Edition13 November 2026 SAGE updates recommendations on fractional-dose yellow fever vaccination
WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization, meeting from 5–8 October 2026, reviewed new evidence on fractional-dose yellow fever vaccination and updated recommendations on its use in outbreak response and preventive vaccination campaigns. The evidence reviewed by SAGE found that a one-fifth fractional dose of yellow fever vaccine elicits an immune response that is non-inferior to a standard dose at 28 days in adults and children aged two years and older. However, seroconversion at 10 days was less consistent, particularly among children, and evidence on the long-term durability of protection in children remains limited. For reactive outbreak response, SAGE reiterated its 2017 recommendation that a one-fifth fractional dose may be used in people aged two years and older when vaccine demand exceeds available supply. Importantly, SAGE also recommended that, for preventive vaccination campaigns, a one-fifth single fractional dose may be used in people aged 2–59 years when vaccine supply, financial or other programme constraints would otherwise limit the timely implementation, scale or coverage of vaccination. For routine and catch-up vaccination in children, SAGE continues to recommend a standard dose, given the currently insufficient evidence on immunogenicity and long-term durability of protection following fractional dosing in this age group. These recommendations provide additional options for yellow fever vaccination programmes to optimize available vaccine supply and extend protection when constraints could otherwise affect preventive campaigns or outbreak response. Access the meeting highlights: Highlights from the Meeting of SAGE on Immunization, 5–8 October 2026 The meeting highlights note that the full SAGE report will be published in the Weekly Epidemiological Record on 18 December 2026 and that only the wording of the full report should be considered final.
Lao PDR strengthens integrated surveillance and response to dengue and other arboviruses
The Ministry of Health of Lao PDR, with support from WHO, convened a national consultation bringing together surveillance, laboratory and clinical experts to strengthen early detection, investigation and response to dengue and other arboviral diseases. Dengue remains one of the country’s highest-priority public health challenges and continues to place a substantial burden on communities and health services. Over two days, participants worked through dengue outbreak scenarios and reviewed the surveillance pathway from alert notification to specimen collection and laboratory confirmation. The consultation resulted in agreement on alert thresholds and triggers for outbreak investigations across different levels of the health system and at community level. The meeting also clarified how laboratory testing should contribute to dengue surveillance. While confirmation is not required for every suspected dengue case, targeted specimen collection and testing are important for monitoring circulating dengue serotypes and detecting other arboviruses, including chikungunya and Zika. Participants also highlighted the role of clinicians in early case detection, reporting and specimen collection, and in connecting patients with laboratories and rapid response teams. The consultation contributes to broader efforts to strengthen health security and arbovirus preparedness in Lao PDR. Importantly for the Gazette, the activity was supported by the Wellcome Trust through the WHO Global Arbovirus Programme, as part of efforts to strengthen country capacities for arbovirus prevention, surveillance, diagnosis and response.
PAHO Member States approve regional strategy to tackle dengue and other arboviral diseases in the Americas
Member States of the Pan American Health Organization (PAHO) have approved a new regional framework to strengthen surveillance, prevention, preparedness and integrated response to dengue and other arboviral diseases across the Americas over the next decade. The framework was adopted during PAHO’s 63rd Directing Council on 1 October 2026. The strategy responds to an increasingly complex arbovirus landscape across the Region, characterized by larger outbreaks, the simultaneous circulation of multiple arboviruses and the geographic expansion of disease vectors. In 2024 alone, the Americas recorded more than 13 million dengue cases and over 8,400 deaths, the largest dengue epidemic on record. The Region has also experienced major chikungunya outbreaks, expansion of Oropouche virus disease beyond its traditional transmission areas and increased yellow fever cases in new geographic locations. A central objective is to support countries in moving from predominantly reactive responses towards more anticipatory and risk-based approaches. The strategy prioritizes integrated arboviral disease management; strengthened epidemiological, entomological and virological surveillance; improved capacity for early detection, diagnosis and clinical management; and more sustainable and innovative approaches to integrated vector management. It also promotes stronger integration of epidemiological, entomological, virological and laboratory data to improve early warning and risk assessment, alongside digital tools, a One Health approach and innovative vector-control technologies, including Wolbachia-infected and irradiated mosquitoes. PAHO will support countries and territories with implementation, guided technically by the Integrated Management Strategy for the Prevention and Control of Arboviral Diseases (EGI-Arbovirus) 2026–2035, featured in the September edition of the Arbovirus Gazette. Progress will be monitored through regional reports scheduled for 2031 and 2036.
WHO publishes Global Yellow Fever Update, 2025
WHO has published the Global Yellow Fever Update, 2025 in the 2 October 2026 edition of the Weekly Epidemiological Record (WER), providing a comprehensive overview of the global yellow fever situation, vaccination progress, surveillance and laboratory capacity, and priorities for sustaining prevention and control efforts. The update highlights contrasting epidemiological trends across the two principal endemic regions. In Africa, 120 laboratory-confirmed cases, including 17 deaths, were reported from 14 countries in 2025. While this represented a modest decline compared with 2024, transmission remained geographically widespread and continued to expose important population immunity gaps. In the Americas, 348 confirmed cases, including 148 deaths, were reported across seven countries, representing a 5.6-fold increase compared with 2024 and reflecting a marked resurgence and geographic expansion of sylvatic transmission. No urban yellow fever transmission or international spread was documented. Significant progress in vaccination nevertheless continued. Since 2017, more than 374 million people in Africa have been protected through preventive, reactive and catch-up vaccination activities. In 2025, preventive mass vaccination campaigns in the Democratic Republic of the Congo, Guinea-Bissau, Niger and Uganda reached more than 29 million people. Global routine yellow fever immunization coverage also increased to 66% in 2025. The update underscores that important immunity gaps remain. It highlights the need to sustain strong routine immunization, identify and close immunity gaps, strengthen surveillance and laboratory networks, and reinforce preparedness for potential urban transmission, increasingly in integration with broader arbovirus prevention and control efforts. As the Eliminate Yellow Fever Epidemics (EYE) Strategy approaches the end of its implementation period, these priorities are also informing development of the EYE Transition and Sustainability Framework, aimed at sustaining progress beyond 2026 through stronger country ownership, continued global and regional coordination, and greater integration with the Global Arbovirus Programme and other relevant health agendas. Access the Weekly Epidemiological Record: Global Yellow Fever Update, 2025
Yellow fever transmission continues across the WHO African Region, with recent activity concentrated in West Africa
WHO has published a new Disease Outbreak News: Yellow fever – WHO African Region, highlighting continued yellow fever transmission across the Region and recent outbreak activity concentrated in parts of West Africa. Between 1 January and 12 October 2026, 67 confirmed cases, including 18 deaths, were reported across nine countries: Burkina Faso, Cameroon, the Central African Republic, Côte d’Ivoire, Ghana, Guinea, Liberia, Nigeria and Togo. Recent outbreak activity has been concentrated in Burkina Faso, Côte d’Ivoire, Ghana and Liberia, including areas close to international borders. Population mobility, occupational and environmental exposure in or near forested areas, uneven vaccination coverage and the presence of competent mosquito vectors contribute to the potential for continued transmission and further geographic and cross-border spread. Countries, supported by WHO and partners, are strengthening surveillance and case investigation, laboratory testing, active case finding, risk communication and community engagement, and preventive and reactive vaccination activities. Cross-border preparedness, information sharing and coordination are particularly important where cases are occurring close to national borders. On 27 October 2026, WHO assessed the overall public health risk associated with the current situation as moderate at the regional level, while the global risk remains low. Continued transmission and additional cases in the African Region are considered likely, particularly in areas with population immunity gaps. WHO continues to emphasize vaccination as the most effective measure for preventing yellow fever, alongside strong surveillance, timely laboratory confirmation, vector control and coordinated preparedness and response. Read the Disease Outbreak News: Yellow fever – WHO African Region: WHO Disease Outbreak News, 6 November 2026
WHO publishes Global Dengue Update with latest trends through August 2026WHO has published a new Global dengue update in the 9 October 2026 edition of the Weekly Epidemiological Record, providing an overview of reported dengue trends worldwide based on data available through the end of August 2026. Between January and August 2026, 2.2 million dengue cases and more than 1,100 deaths were reported from 97 countries, territories and areas. Globally, reported transmission during this period was lower than during the same period in 2024 and 2025, when 12.7 million and 4.4 million cases, respectively, had been reported by the end of August. Despite the lower global total, the epidemiological picture remains heterogeneous. Twenty-seven countries, territories and areas reported higher cumulative case numbers between January and August 2026 than during the same period in either 2024 or 2025. Brazil reported the largest number of cases in 2026, with more than 1.2 million, followed by Viet Nam with 106,767 and Sri Lanka with 95,545. WHO notes that differences in case definitions and ascertainment between countries should be considered when interpreting these data. The update also highlights WHO's almost real-time global dengue surveillance system, established in 2024 and currently incorporating monthly data from 185 countries, territories and areas. The global dengue dashboard brings these surveillance data together with information including genomic data, modelled risk estimates and visualizations of seasonal patterns. More than 53,000 dengue virus sequences from all six WHO regions have also been submitted to GenBank, providing additional information on the global diversity and evolution of circulating dengue viruses. Access the Global dengue update: WHO Weekly Epidemiological Record
WHO EPI-WIN highlights integrated clinical management of dengue, chikungunya, Zika and yellow fever
On 4 November 2026, WHO Health Emergencies EPI-WIN hosted a webinar focused on the WHO guidelines for clinical management of arboviral diseases: dengue, chikungunya, Zika and yellow fever. The session brought attention to evidence-based recommendations and practical implementation tools to support health-care providers in managing suspected and confirmed arboviral disease across different levels of the health system. The integrated guidelines address both non-severe cases managed in outpatient settings and severe disease requiring hospitalization. Covering dengue, chikungunya, Zika and yellow fever together reflects the clinical challenges posed by diseases that can present with similar symptoms, particularly in settings where several arboviruses circulate simultaneously and access to diagnostic testing may be limited. The webinar highlighted the importance of translating clinical recommendations into practice, including through strengthened referral pathways and access to hospital and critical care for patients with severe disease. The session also demonstrated implementation tools derived from the guidelines and emphasized continued investment in health infrastructure, referral systems and clinical capacity. Learn more: WHO EPI-WIN webinar on clinical management of arboviral diseases Access the guidelines: WHO guidelines for clinical management of arboviral diseases: dengue, chikungunya, Zika and yellow fever
WHO advances the Global One Health Arbovirus Network (GO-ArboNet)
WHO has launched the Global One Health Arbovirus Network (GO-ArboNet), a WHO-managed collaborative network designed to connect and strengthen existing networks working on arboviruses and other emerging zoonotic viral threats. GO-ArboNet aims to strengthen coordination and information exchange across networks and sectors, enhance diagnostic preparedness and response, facilitate timely, trusted and equitable sharing of data and specimens, and promote greater operational efficiency and collective impact. Designed as a “network of networks,” GO-ArboNet will bring together established surveillance, One Health, vector surveillance and control, laboratory, research and technical networks while preserving their respective mandates and autonomy. WHO will serve as the Secretariat, supported by strategic advice from TAG-Arboviruses, the Network Representatives Group and thematic Working Groups. The Call for Expressions of Interest closed on 1 November 2026, following an invitation to eligible national, regional and international networks and collaborative platforms to express interest in joining the initiative.
Key events and engagement opportunities
Joint Meeting of EPI Programme Managers from West and Central Africa (EPILOM26)
2nd Dengue in the Americas Summit
American Society of Tropical Medicine and Hygiene (ASTMH) 2026 Annual Meeting
1st Annual Meeting of the Dengue-Zika (DeZi) Network
Tell us your news!We would love to showcase the work you are doing on protecting people from arboviruses. To submit your news, stories, photos and videos, please email: arbovirusinfo@who.int To read the EYE Strategy, click here
To read the GLAI, click here
Copyright © 2026 World Health Organization, All rights reserved.
|
Arbovirus Gazette - October 2026 Edition
Subscribe to:
Post Comments (Atom)

No comments:
Post a Comment